1. Scrip
  2. >>Business

After J&J Vaccine Pause, Urgent Safety Questions for Sputnik And CanSino

Is This A ‘Class Effect’?

 
• By Andrew McConaghie

Potentially fatal blood clots seen in AZ and J&J’s COVID-19 vaccine could be common to all adenovirus vector vaccines – but Russia and China developers are dismissing a possible link.

Sputnik V vaccine
Sputnik V's Ad26 viral vector is similar to J&J's vaccine - leading many experts to suspect there could be a class effect. • Source: Getty Images

Johnson & Johnson’s COVID-19 vaccine has become the second to be linked to very rare but potentially life-threatening blood clots.

Now one of the big questions is: could this be a “class effect” affecting all adenovirus vector-based vaccines

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.